News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,340 Results
Type
Article (14937)
Company Profile (300)
Press Release (268097)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80197)
Career Advice (187)
Deals (13372)
Drug Delivery (39)
Drug Development (50703)
Employer Resources (31)
FDA (5854)
Job Trends (5175)
News (145530)
Policy (10110)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21819)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6048)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4562)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3133)
Cardiovascular disease (237)
Career advice (163)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43669)
Collaboration (1149)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1102)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4318)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1440)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31841)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51775)
Executive appointments (623)
FDA (7602)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (981)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6617)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1207)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (23)
IPO (7358)
IRA (12)
Job creations (873)
Job search strategy (145)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (244)
Leadership (9)
Legal (1422)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2670)
Medtech (2679)
Mergers & acquisitions (6638)
Metabolic disorders (725)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1950)
Neurotech (1)
NextGen: Class of 2026 (2041)
Non-profit (868)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26751)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15477)
Phase 2 (20287)
Phase 3 (12821)
Pipeline (3240)
Policy (90)
Postmarket research (853)
Preclinical (6536)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1457)
Recruiting (12)
Regulatory (9907)
Reports (20)
Research institute (975)
Resumes & cover letters (24)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (6)
Last 7 days (344)
Last 30 days (1349)
Last 365 days (17853)
2026 (1653)
2025 (18122)
2024 (20605)
2023 (22477)
2022 (27152)
2021 (28143)
2020 (23533)
2019 (16297)
2018 (11783)
2017 (13785)
2016 (11887)
2015 (14393)
2014 (10448)
2013 (7551)
2012 (7614)
2011 (7668)
2010 (7468)
Location
Africa (155)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18273)
Australia (3111)
California (7093)
Canada (1837)
China (772)
Colorado (251)
Connecticut (252)
Delaware (235)
Europe (39232)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (396)
India (36)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5579)
Michigan (111)
Minnesota (247)
Mississippi (3)
Missouri (35)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3488)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (218)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (905)
United States (23349)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
283,340 Results for "biora therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Biora Therapeutics Successfully Completes Restructuring Process
April 1, 2025
·
2 min read
Biotech Beach
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today shared positive topline results from its clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment of patients with ulcerative colitis (UC).
July 1, 2024
·
9 min read
Biotech Beach
Biora Therapeutics Provides Outlook for 2024
Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, provided guidance on anticipated milestones during 2024.
January 16, 2024
·
7 min read
Business
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024.
May 7, 2024
·
3 min read
Business
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
May 15, 2024
·
11 min read
Biotech Beach
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Biora Therapeutics, Inc. today announced an agreement with institutional investor Context Capital to invest $2.8 million in new capital.
March 11, 2024
·
5 min read
Biotech Beach
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Biora Therapeutics, Inc today announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600.
April 30, 2024
·
7 min read
Biotech Beach
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Biora Therapeutics, Inc. presented a poster titled “Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC” at the Digestive Disease Week® conference in Washington DC, on Sunday, May 19, 2024.
May 20, 2024
·
6 min read
Biotech Beach
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
Biora Therapeutics, Inc. announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston.
June 11, 2024
·
5 min read
Biotech Beach
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
Biora Therapeutics, Inc today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024.
February 8, 2024
·
3 min read
1 of 28,334
Next
